| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -85,484 | -79,457 |
| Depreciation and amortization | 7,935 | 5,346 |
| Accretion of discount on marketable debt securities, net | 3,141 | 1,489 |
| Stock-based compensation | 33,042 | 22,950 |
| Gain on sale of marketable securities, net | 4,973 | 5,380 |
| Change in fair value of marketable equity securities | 45,136 | 528 |
| Asset impairment charges | 8,288 | 6,723 |
| Non-cash royalty revenue related to the sale of future royalties | 57,828 | 36,831 |
| Non-cash interest expense on liabilities related to the sale of future royalties | 24,569 | 16,906 |
| Accounts receivable | -34,532 | -14,636 |
| Prepaid expenses and other assets | -8,761 | -3,504 |
| Accounts payable | -5,644 | 3,810 |
| Accrued expenses | 6,854 | 2,631 |
| Operating lease, net | 890 | 877 |
| Other assets and liabilities, net | 6,071 | 6,287 |
| Net cash used in operating activities | -83,406 | -52,589 |
| Purchase of marketable debt securities | 261,045 | 176,810 |
| Purchase of property and equipment | 2,010 | 1,827 |
| Purchase of patents | 0 | 0 |
| Proceeds from sales of marketable equity securities | 13,778 | 13,399 |
| Proceeds from sales and maturities of marketable debt securities | 318,089 | 219,382 |
| Net cash provided by (used in) investing activities | 68,812 | 54,144 |
| Proceeds from the exercises of stock options | 2,974 | 2,974 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 662 | 662 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 | - |
| Common stock and pre-funded warrants issuance costs | 0 | - |
| Cash paid to acquire noncontrolling interest | 1,725 | 1,725 |
| Net cash provided by financing activities | 1,911 | 1,911 |
| Net decrease in cash, cash equivalents, and restricted cash | -12,683 | 3,466 |
| Cash and cash equivalents at beginning of period | 41,262 | - |
| Cash and cash equivalents at end of period | 28,579 | - |
Xencor Inc (XNCR)
Xencor Inc (XNCR)